PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
GNLX vs. RXRX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between GNLX and RXRX is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

GNLX vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Genelux Corporation (GNLX) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

0.00%50.00%100.00%150.00%SeptemberOctoberNovemberDecember2025February
119.09%
40.82%
GNLX
RXRX

Key characteristics

Sharpe Ratio

GNLX:

-0.34

RXRX:

-0.25

Sortino Ratio

GNLX:

0.23

RXRX:

0.22

Omega Ratio

GNLX:

1.03

RXRX:

1.03

Calmar Ratio

GNLX:

-0.40

RXRX:

-0.25

Martin Ratio

GNLX:

-0.62

RXRX:

-0.43

Ulcer Index

GNLX:

61.80%

RXRX:

49.53%

Daily Std Dev

GNLX:

113.45%

RXRX:

86.39%

Max Drawdown

GNLX:

-95.74%

RXRX:

-88.97%

Current Drawdown

GNLX:

-87.32%

RXRX:

-74.96%

Fundamentals

Market Cap

GNLX:

$180.63M

RXRX:

$4.25B

EPS

GNLX:

-$0.94

RXRX:

-$1.54

Total Revenue (TTM)

GNLX:

$8.00K

RXRX:

$54.29M

Gross Profit (TTM)

GNLX:

-$444.00K

RXRX:

$14.55M

EBITDA (TTM)

GNLX:

-$20.22M

RXRX:

-$262.33M

Returns By Period

In the year-to-date period, GNLX achieves a 104.24% return, which is significantly higher than RXRX's 53.11% return.


GNLX

YTD

104.24%

1M

66.78%

6M

119.09%

1Y

-34.95%

5Y*

N/A

10Y*

N/A

RXRX

YTD

53.11%

1M

50.44%

6M

40.82%

1Y

-16.33%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

GNLX vs. RXRX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNLX
The Risk-Adjusted Performance Rank of GNLX is 3232
Overall Rank
The Sharpe Ratio Rank of GNLX is 2929
Sharpe Ratio Rank
The Sortino Ratio Rank of GNLX is 3838
Sortino Ratio Rank
The Omega Ratio Rank of GNLX is 3838
Omega Ratio Rank
The Calmar Ratio Rank of GNLX is 2323
Calmar Ratio Rank
The Martin Ratio Rank of GNLX is 3333
Martin Ratio Rank

RXRX
The Risk-Adjusted Performance Rank of RXRX is 3535
Overall Rank
The Sharpe Ratio Rank of RXRX is 3333
Sharpe Ratio Rank
The Sortino Ratio Rank of RXRX is 3838
Sortino Ratio Rank
The Omega Ratio Rank of RXRX is 3737
Omega Ratio Rank
The Calmar Ratio Rank of RXRX is 3131
Calmar Ratio Rank
The Martin Ratio Rank of RXRX is 3737
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

GNLX vs. RXRX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Genelux Corporation (GNLX) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for GNLX, currently valued at -0.34, compared to the broader market-2.000.002.00-0.34-0.25
The chart of Sortino ratio for GNLX, currently valued at 0.23, compared to the broader market-4.00-2.000.002.004.006.000.230.22
The chart of Omega ratio for GNLX, currently valued at 1.03, compared to the broader market0.501.001.502.001.031.03
The chart of Calmar ratio for GNLX, currently valued at -0.40, compared to the broader market0.002.004.006.00-0.40-0.33
The chart of Martin ratio for GNLX, currently valued at -0.62, compared to the broader market-10.000.0010.0020.0030.00-0.62-0.43
GNLX
RXRX

The current GNLX Sharpe Ratio is -0.34, which is lower than the RXRX Sharpe Ratio of -0.25. The chart below compares the historical Sharpe Ratios of GNLX and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.50SeptemberOctoberNovemberDecember2025February
-0.34
-0.25
GNLX
RXRX

Dividends

GNLX vs. RXRX - Dividend Comparison

Neither GNLX nor RXRX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

GNLX vs. RXRX - Drawdown Comparison

The maximum GNLX drawdown since its inception was -95.74%, which is greater than RXRX's maximum drawdown of -88.97%. Use the drawdown chart below to compare losses from any high point for GNLX and RXRX. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%-30.00%SeptemberOctoberNovemberDecember2025February
-87.32%
-34.74%
GNLX
RXRX

Volatility

GNLX vs. RXRX - Volatility Comparison

Genelux Corporation (GNLX) has a higher volatility of 38.76% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 29.87%. This indicates that GNLX's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


15.00%20.00%25.00%30.00%35.00%40.00%SeptemberOctoberNovemberDecember2025February
38.76%
29.87%
GNLX
RXRX

Financials

GNLX vs. RXRX - Financials Comparison

This section allows you to compare key financial metrics between Genelux Corporation and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab